2016
Proton-Pump Inhibitors Reduce Gastrointestinal Events Regardless of Aspirin Dose in Patients Requiring Dual Antiplatelet Therapy
Vaduganathan M, Bhatt DL, Cryer BL, Liu Y, Hsieh WH, Doros G, Cohen M, Lanas A, Schnitzer TJ, Shook TL, Lapuerta P, Goldsmith MA, Laine L, Cannon CP, Investigators C. Proton-Pump Inhibitors Reduce Gastrointestinal Events Regardless of Aspirin Dose in Patients Requiring Dual Antiplatelet Therapy. Journal Of The American College Of Cardiology 2016, 67: 1661-1671. PMID: 27012778, DOI: 10.1016/j.jacc.2015.12.068.Peer-Reviewed Original ResearchMeSH KeywordsAgedAspirinClopidogrelDose-Response Relationship, DrugDrug Therapy, CombinationDyspepsiaFemaleGastrointestinal HemorrhageHumansIntestinal ObstructionIntestinal PerforationMaleMiddle AgedMyocardial InfarctionMyocardial RevascularizationOmeprazolePainPeptic UlcerPlatelet Aggregation InhibitorsProspective StudiesProton Pump InhibitorsStrokeTiclopidineConceptsDual antiplatelet therapyLow-dose aspirinProton pump inhibitorsMajor adverse cardiac eventsAdverse cardiac eventsPPI therapyAntiplatelet therapyAspirin usersGastrointestinal eventsCardiac eventsGI eventsMeier estimatesArtery diseaseCardiovascular endpointsLow-dose aspirin usersPrimary cardiovascular endpointUpper GI eventsHigh-dose aspirinPeripheral artery diseasePercutaneous coronary interventionCoronary artery diseaseHigh rateAspirin groupBlinded gastroenterologistsAspirin dose
2012
Safety and Efficacy of High- Versus Low-Dose Aspirin After Primary Percutaneous Coronary Intervention in ST-Segment Elevation Myocardial Infarction The HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) Trial
Yu J, Mehran R, Dangas GD, Claessen BE, Baber U, Xu K, Parise H, Fahy M, Lansky AJ, Witzenbichler B, Grines CL, Guagliumi G, Kornowski R, Wöhrle J, Dudek D, Weisz G, Stone GW. Safety and Efficacy of High- Versus Low-Dose Aspirin After Primary Percutaneous Coronary Intervention in ST-Segment Elevation Myocardial Infarction The HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) Trial. JACC Cardiovascular Interventions 2012, 5: 1231-1238. PMID: 23257371, DOI: 10.1016/j.jcin.2012.07.016.Peer-Reviewed Original ResearchConceptsPrimary percutaneous coronary interventionST-segment elevation myocardial infarctionLow-dose aspirinElevation myocardial infarctionHigh-dose aspirinPrimary PCIHORIZONS-AMI trialPercutaneous coronary interventionMyocardial infarctionMajor bleedingCoronary interventionIschemic target vessel revascularizationMajor adverse cardiovascular eventsCoronary artery bypass surgeryLong-term patient outcomesAdverse ischemic eventsAdverse cardiovascular eventsDose of aspirinTarget vessel revascularizationArtery bypass surgeryHistory of hypertensionPremature coronary diseaseLong-term outcomesIschemic benefitAspirin dose
2011
IMPACT OF ASPIRIN DOSE ON LONG TERM CLINICAL OUTCOMES AFTER STENTING FOR ACUTE MYOCARDIAL INFARCTION: 3-YEAR FOLLOW-UP DATA FROM THE HORIZONS-AMI TRIAL
Kovacic J, Mehran R, Dangas G, Claessen B, Parise H, Fahy M, Lansky A, Witzenbichler B, Grines C, Guagliumi G, Kornowski R, Wöhrle J, Dudek D, Weisz G, Stone G. IMPACT OF ASPIRIN DOSE ON LONG TERM CLINICAL OUTCOMES AFTER STENTING FOR ACUTE MYOCARDIAL INFARCTION: 3-YEAR FOLLOW-UP DATA FROM THE HORIZONS-AMI TRIAL. Journal Of The American College Of Cardiology 2011, 57: e1633. DOI: 10.1016/s0735-1097(11)61633-1.Peer-Reviewed Original Research
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply